Bioxytran (BIXT) Cash from Financing Activities (2010 - 2026)
Bioxytran (BIXT) posted Cash from Financing Activities of $200970.0 for Q1 2026, down 72.79% sequentially from $738626.0 in Q4 2025, and up 20.68% YoY from $166532.0 in Q1 2025.
Bioxytran (BIXT) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Bioxytran has reported Cash from Financing Activities for 16 years, with the latest figure at $200970.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 20.68% year-over-year to $200970.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 138.96% YoY) and the FY2025 annual result came in at $1.1 million, up 171.32% from the prior year.
- Cash from Financing Activities declined to $200970.0 in Q1 2026 per BIXT's latest filing, from $738626.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $1.4 million in Q1 2022 and troughed at $45000.0 in Q4 2023.
- A 5-year average of $265823.4 and a median of $102509.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities slumped 96.38% in 2023, then surged 568.5% in 2025.
- Over 5 years, Cash from Financing Activities stood at $78000.0 in 2022, then sank by 42.31% to $45000.0 in 2023, then surged by 145.53% to $110490.0 in 2024, then soared by 568.5% to $738626.0 in 2025, then tumbled by 72.79% to $200970.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $200970.0, $738626.0, and $54503.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 73,493.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 200,970.00 |
| Mar 31, 2026 | 200,970.00 |
| Dec 31, 2025 | 738,626.00 |
| Dec 31, 2025 | 738,626.00 |
| Sep 30, 2025 | 54,503.00 |
| Sep 30, 2025 | 54,503.00 |
| Jun 30, 2025 | 94,645.00 |
| Jun 30, 2025 | 94,645.00 |
| Mar 31, 2025 | 166,532.00 |
| Mar 31, 2025 | 166,532.00 |
| Dec 31, 2024 | 110,490.00 |
| Dec 31, 2024 | 110,490.00 |
| Sep 30, 2024 | 105,518.00 |
| Sep 30, 2024 | 105,518.00 |
| Jun 30, 2024 | 73,070.00 |
| Jun 30, 2024 | 73,070.00 |
| Mar 31, 2024 | 99,500.00 |
| Mar 31, 2024 | 99,500.00 |
| Dec 31, 2023 | 45,000.00 |
| Dec 31, 2023 | 45,000.00 |